First Analysis Of Extended Dosing With Celgene International Sárl (CELG) Epigenetic Agent CC-486 In Patients With Higher-Risk Myelodysplastic Syndromes Presented At American Society of Hematology
12/9/2013 9:53:46 AM
BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from an ad hoc analysis of a subset of subjects with higher-risk myelodysplastic syndrome (MDS) from two ongoing phase I/II studies of oral epigenetic agent CC-486 (oral azacitidine) were presented at the American Society of Hematology annual meeting in New Orleans, La.
Help employers find you! Check out all the jobs and post your resume.
comments powered by